Drug Companies Are Lowering Out of Pocket Inhaler Costs to $35
It seems like all Congress does lately is fight. They don't seem to get any actual work done as neither side can agree on legislation. But it was interesting to see that the Senate Health, Education and Labor (HELP) committee was investigating high price inhalers. In January, the HELP committee had contacted all 4 manufacturers of inhalers to ask why inhalers cost so much more in the US than they do in other countries. They gave a few examples: Advair costs $319 in the U.S. - but only $26 in the U.K. QVAR costs $286 in the U.S. - but only $9 in Germany. Combivent Respimat costs $489 in the U.S. – but only $7 in France. In March, AstraZeneca announced it was lowering out of pocket costs to $35 (starting in June.) If you use any of these inhalers, they will cost less out of pocket when summer comes. Also in March, Boehringer Ingelheim announced it was lowering out of pocket costs to $35, (also starting in June.) These inhalers will also cost ...